Rilzabrutinib ITP denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for rilzabrutinib itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Rilzabrutinib for ITP as Duplicate Therapy

A duplicate-therapy denial for rilzabrutinib (a BTK inhibitor being evaluated for immune thrombocytopenia, or ITP) from Cigna means the insurer identified another active claim or active prescription in your record that it classifies as addressing the same treatment goal. In ITP, this most often occurs when a patient is also receiving another thrombopoietin receptor agonist (TPO-RA), another immunosuppressant, or another agent that Cigna's formulary management system groups with rilzabrutinib under a common therapeutic category. Because rilzabrutinib acts through a distinct mechanism (BTK inhibition) compared with agents such as corticosteroids, IVIG, rituximab, or TPO-RAs, the duplicate-therapy label frequently reflects a formulary-category coding overlap rather than a genuine therapeutic duplication.

## Why This Denial Is Appealable

BTK inhibitors represent a mechanistically distinct class from other ITP treatments. An appeal that documents the different mechanism of action, the clinical rationale for combination or sequential use, and the inadequacy of the currently active agent for this patient has a strong basis for reversal. The key is distinguishing mechanism and clinical role, not just drug names.

## Federal Appeal Rights

• Internal appeal: File under ERISA §503 (self-funded) or applicable state law (fully-insured) within the deadline on your denial letter — typically 180 days.
• External review: ACA §2719 provides access to an IRO after final internal denial, generally within four months. External reviewers apply clinical pharmacology standards and are not bound by formulary-category groupings.
• Expedited review: If ITP is causing active bleeding risk or urgent platelet-count concern, request expedited review for a 72-hour decision.

## Concrete Appeal Steps

1. Identify the specific agent Cigna has flagged as duplicative — this should be stated in the denial rationale or obtainable by calling Cigna's clinical review line. 2. Have your hematologist write a letter explaining the mechanism-of-action distinction and the clinical rationale for rilzabrutinib in your specific case. 3. Document why the currently active agent is inadequate (insufficient response, intolerance, or contraindication per your physician's judgment). 4. Compile the full documentation package and submit before the internal deadline.

## Documentation to Gather

• Diagnosis confirmation: Hematology notes and laboratory records confirming the ITP diagnosis, chronicity, and current platelet count and bleeding status.
• Treatment history: A chronological list of all prior ITP treatments — including corticosteroids, IVIG, anti-D, TPO-RAs, rituximab, and any other agents — with dates, doses (from the medical record, not asserted here), and documented responses or reasons for discontinuation.
• Inadequacy of current/prior therapy: Chart notes documenting that the agent flagged as "duplicative" has been inadequate, not tolerated, or is being used in a different clinical context.
• Prescriber medical-necessity letter: A letter from the treating hematologist or immunologist explaining rilzabrutinib's mechanistic distinction, the clinical rationale for prescribing it, and why it is not duplicative of any agent currently on file.
• Clinical severity: Current platelet counts, bleeding event records, and quality-of-life impact documentation.

## Criteria-Mapping Structure

Obtain Cigna's drug coverage policy and the specific duplicate-therapy rationale, then address each point:

| Cigna's Duplicate-Therapy Basis (from denial or policy) | Clinical Counter-Evidence | |---|---| | [Agent identified as duplicative] | [Mechanism-of-action distinction; different drug class] | | [Formulary category grouping] | [Physician letter explaining distinct therapeutic role] | | [Requirement that prior agent be trialed/failed] | [Treatment history with documented inadequacy] | | [Any combination-therapy restriction] | [Clinical rationale for the specific use case] |

The central argument — that mechanistic distinction makes rilzabrutinib non-duplicative — is most persuasive when paired with concrete evidence that the flagged agent did not achieve adequate disease control for this patient.